Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/780366

Contents of this Issue

Navigation

Page 41 of 47

40 Clinical OMICs January/February 2017 www.clinicalomics.com Precision Medicine Omics, Biology Meet Artificial Intelligence iCarbonX Launches Digital Health Alliance to Move Healthcare Past Genetics to Wellness Predictions Diana Manos, Contributing Editor J un Wang, Ph.D., CEO of iCarbonX, a China-based artifi- cial intelligence (AI) start-up, has announced the launch of a new digital life alliance that will aim to improve health and wellness on a grand scale. The alliance of seven omics, AI, and bio companies will work together as an "ecosystem," Wang announced January 5 at the Digital Health Summit. iCarbonX, launched in 2015, plans to back the alliance with $400 million in venture capi- tal, to drive wellness research and the advancement of digital technology to guide individuals toward staying well. The companies to form the alliance include: • SomaLogic, a provider of proteomics technology to transform life sciences research and medicine; • HealthTell, a provider of ImmunoSignature technology; • PatientsLikeMe, the world's largest personalized health network; • AOBiome, developer of a probiotic-based therapy designed to restore ammonia oxidizing bacteria (AOB) to the human microbiome; • GALT (General Automation Lab Technologies), a developer of high-throughput microbial detection and isolation products; • Imagu, designer of a digitalized human model to understand, predict and infer information about an individual's health; and • Robustnique Corp. Ltd., a technology-driven company committed to developing recombinant enzymes and high-end cosmetics. Dr. Wang said the alliance's ultimate goal is to detect "meaningful signals" about health, disease and aging. "We can only reach this audacious goal if we successfully inte- grate traditionally separate fields of expertise into one col- laborative ecosystem," he said. "Today we know a great deal about how genes impact our health," Dr. Wang said. "But for that knowledge to be useful, we need to know how disease and aging manifest in the body over time, and how our everyday choices affect their progression." Dr. Wang said the new ecosystem "will be capable of con- necting the biology and experience of individuals, and of creating useful, predictive algorithms to illuminate personal susceptibilities, differences in body functions and variations in treatment responses." Jun Wang, Ph.D., CEO of iCarbonX. iCarbonX

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017